iGii promotes James Youell to spearhead sales of groundbreaking point-of-care diagnostic technology, Gii-Sens

Stirling, 31 January 2024 – Integrated Graphene, the electrochemistry specialists behind Gii™, a three-dimensional nanomaterial with the revolutionary properties of graphene but none of the scaleup challenges, today promoted James Youell to Sales Director.

In his new role, James will focus on driving sales of Gii-Sens™, the company’s highly sensitive and accurate biosensor technology, and developing strategic alliances with keystone customers and innovators in healthcare.

When integrated with customers’ point-of-care tests, Gii-Sens™ can deliver laboratory-level precision testing outside of clinical settings for a range of indications, including but not limited to, cancer, pathogens, liver and heart failure.

Top of the range point-of-care electrochemical biosensors currently use gold and other expensive materials to offer this level of sensitivity. Gii-Sens™ has been proven to outperform or equal all traditional sensing electrode materials, including gold, at a much lower cost.

Integrated Graphene’s CEO, Jean-Christophe Granier, said: “Imagine if instead of waiting days and weeks to receive diagnostic test results from a lab, you could get those results in a matter of minutes, or even seconds. That’s what we can deliver with Gii-Sens™.

“Gii-Sens™ enables our customers to produce highly sensitive point-of-care tests that deliver repeatable and reliable results at-home, and at a fraction of the cost.

“Over the next 12-months, we are laser-focused on bringing this technology to market, and I can think of no better person to lead that process than James.”

James Youell holds a PhD in Biochemistry from the University of Southampton and was a research fellow at the University of Portsmouth before moving into sales. Prior to joining Integrated Graphene, he spent over a decade leading sales teams at some of the UK’s leading life sciences businesses, including Thermo Fisher Scientific, Promega, and Meridian Life Sciences.

James added: “As a scientist, I am happiest when driving innovation that delivers genuinely life-changing benefits. Working closely with our customers, we will revolutionise point-of-care testing, reduce the burden on healthcare systems globally, and transform lives.”

“With Gii-Sens™, not only can we significantly enhance the capabilities of at-home diagnostics, but we can also deliver sustainability benefits for our customers. Whether that’s through reducing the need to procure mined precious metals, or by reducing the carbon footprint of their supply chain with our chemical free manufacturing process.

“We have already made huge progress in developing our commercial relationships for Gii-Sens™, and I’m hugely excited for everything the future holds.”

Integrated Graphene has developed relationships with healthcare innovators to introduce Gii-Sens™ to point-of-care testing in the United Kingdom, United States, European Union, Australia and New Zealand.